NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market on Monday that its fourth quarter revenues fell nearly 10 percent, despite a 69 percent increase in product revenues driven by an increase in sales of its T2Candida panel.

For the three-month period ended Dec. 31, T2's revenues fell to $910,000 from $1.0 million in the same period the year before, missing the Wall Street consensus estimate for revenues of $1.4 million.

Product revenues rose to $579,000 from $343,000 in Q4 2015. Meanwhile, the company reported research revenues of $331,000.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.